Upregulation of a small subset of genes drives type I interferon-induced antiviral memory

Journal of Interferon and Cytokine Research

Volumn 27, Issue 8, 2007, Pages 653-664

  Jaitin, Diego A ^a   Schreiber, Gideon ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEASOME; PROTEIN DERIVATIVE; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; ANTIVIRUS AGENT;

ANTIGEN PRESENTATION; ARTICLE; GENE; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOLOGICAL MEMORY; MELANOMA DIFFERENTIATION ASSOCIATED GENE 5; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION; CELL LINE; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; PHYSIOLOGY; VESICULAR STOMATITIS VIRUS;

ANTIVIRAL AGENTS; CELL LINE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON TYPE I; UP-REGULATION; VESICULAR STOMATITIS-INDIANA VIRUS;

EID: 35448938101     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2006.0162     Document Type: Article

References (44)

1. Katze MG, He Y, Gale MJ. Viruses and interferon: a fight for supremacy. Nat. Rev. Immunol. 2002;2:675-687.
2. Haller O, Kochs G, Weber F. The interferon response circuit: induction and suppression by pathogenic viruses. Virology 2006;344:119-130.
3. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J. Exp. Med. 2005;202:637-650.
4. Stark GR, Kerr JM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu. Rev. Biochem. 1998;67:227-264.
5. Platanias LC. Mechanisms of type-I- and type-II interferon-mediated signalling. Nat. Rev. Immunol. 2005;5:375-386.
6. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc. Natl. Acad. Sci. USA 1998;95:15623-15628.
7. Pfeffer LM, Dinarello CA, Herberman RB, Williams BR, Borden EC, Bordens R, Walter MR, Nagabhushan TL, Trotta PP, Pestka S. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 1998;58:2489-2499.
8. Jaitin DA, Roisman LC, Jaks E, Gavutis M, Piehler J, Van der Heyden J, Uze G, Schreiber G. Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta. Mol. Cell. Biol. 2006;26:1888-1897.
9. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S, Fujita T. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 2004;5:730-737.
10. Andrejeva J, Childs KS, Young DF, Carlos TS, Stock N, Goodbourn S, Randall RE. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc. Natl. Acad. Sci. USA 2004;101:17264-17269.
11. Yoneyama M, Suhara W, Fukuhara Y, Fukuda M, Nishida E, Fujita T. Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J. 1998;17:1087-1095.
12. Schafer SL, Lin R, Moore PA, Hiscott J, Pitha PM. Regulation of type I interferon gene expression by interferon regulatory factor-3. J. Biol. Chem. 1998;273:2714-2720.
13. Schulz O, Diebold SS, Chen M, Naslund TI, Nolte MA, Alexopoulou L, Azuma YT, Flavell RA, Liljestrom P, Reis e Sousa C. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005;433:887-892.
14. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, Shimada N, Ohba Y, Takaoka A, Yoshida N, Taniguchi T. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005;434:772-777.
15. Piehler J, Roisman LC, Schreiber G. New structural and functional aspects of the IFN-receptor interaction revealed by comprehensive mutational analysis of the binding interface. J. Biol. Chem. 2000;275:40425-40433.
16. Piehler J, Schreiber G. Biophysical analysis of the interaction of human IFNAR-2 expressed in E. coli with IFNa2. J. Mol. Biol. 1999;289:57-67.
17. Rubinstein S, Familletti PC, Pestka S. Convenient assay for interferons. J. Virol. 1981;37:755-758.
18. Novick D, Nabioullin RR, Ragsdale W, McKenna S, Weiser W, Garone L, Burkins C, Kim SH, Rubinstein M, Tepper MA, Arulanandam AR. The neutralization of type I IFN biologic actions by anti-IFNAR-2 monoclonal antibodies is not entirely due to inhibition of Jak-Stat tyrosine phosphorylation. J. Interferon Cytokine Res. 2000;20:971-982.
19. Kesmir C, van Noort V, de Boer RJ, Hogeweg P. Bioinformatic analysis of functional differences between the immunoproteasome and the constitutive proteasome. Immunogenetics 2003;55:437-449.
20. Vieira AV, Lamaze C, Schmid SL. Control of EGF receptor signaling by clathrin-mediated endocytosis. Science 1996;274:2086-2089.
21. Ceresa BP, Schmid SL. Regulation of signal transduction by endocytosis. Curr. Opin. Cell Biol. 2000;12:204-210.
22. Marchetti M, Monier MN, Fradagrada A, Mitchell K, Baychelier F, Eid P, Johannes L, Lamaze C. Stat-mediated signaling induced by type I and type II interferons (IFNs) is differentially controlled through lipid microdomain association and clathrin-dependent endocytosis of IFN receptors. Mol. Biol. Cell 2006;17:2896-2909.
23. Kalie E, Jaitin DA, Abramovich R, Schreiber G. An IFNalpha 2 mutant optimized by phage-display for IFNAR1 binding confers specifically enhanced antitumor activities. J. Biol. Chem. 2007;282:11602-11611.
24. Rostaing L, Chatelut E, Payen JL, Izopet J, Thalamas C, Ton-That H, Pascal JP, Durand D, Canal P. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J. Am. Soc. Nephrol. 1998;9:2344-2348.
25. Shechter Y, Preciado-Patt L, Schreiber G, Fridkin M. Prolonging the half-life of human interferon-a2 in circulation: design, preparation and analysis of [2-sulfo-9-fluorenylmethoxycarbonyl]7-interferon-a2 [FMS7-interferon-a2]. Proc. Natl. Acad. Sci. USA 2001;98:1212-1217.
26. Dupont SA, Goelz S, Goyal J, Green M. Mechanisms for regulation of cellular responsiveness to human IFN-β1a. J. Interferon Cytokine Res. 2002;22:491-501.
27. 1 arrest, differentiation and apoptosis of the Daudi B-cell line. Oncogene 1998;16:1885-1890.
28. Raveh T, Hovanessian AG, Meurs EF, Sonenberg N, Kimchi A. Double-stranded RNA-dependent protein kinase mediates c-Myc suppression induced by type I interferons. J. Biol. Chem. 1996;271:25479-25484.
29. Williams BR. PKR, a sentinel kinase for cellular stress. Oncogene 1999;18:6112-6120.
30. Silverman RH. Fascination with 2-5A-dependent RNase: a unique enzyme that functions in interferon action. J. Interferon Res. 1994;14:101-104.
31. Haller O, Kochs G. Interferon-induced mx proteins: dynamin-like GTPases with antiviral activity. Traffic 2002;3:710-717.
32. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 1957;147:258-267.
33. Kang DC, Gopalkrishnan RV, Wu Q, Jankowsky E, Pyle AM, Fisher PB. Mda-5: An interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc. Natl. Acad. Sci. USA 2002;99:637-642.
34. Garcia-Sastre A, Biron CA. Type 1 interferons and the virus-host relationship: a lesson in detente. Science 2006;312:879-882.
35. Yoneyama M, Kikuchi M, Matsumoto K, Imaizumi T, Miyagishi M, Taira K, Foy E, Loo YM, Gale MJ, Akira S, Yonehara S, Kato A, Fujita T. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J. Immunol. 2005;175:2851-2858.
36. Rothenfusser S, Goutagny N, DiPerna G, Gong M, Monks BG, Schoenemeyer A, Yamamoto M, Akira S, Fitzgerald KA. The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I. J. Immunol. 2005;175:5260-5268.
37. Kulski JK, Dawkins RL. The P5 multicopy gene family in the MHC is related in sequence to human endogenous retroviruses HERV-L and HERV-16. Immunogenetics 1999;49:404-412.
38. Khan S, van den Broek M, Schwarz K, de Giuli R, Diener PA, Groettrup M. Immunoproteasomes largely replace constitutive proteasomes during an antiviral and antibacterial immune response in the liver. J. Immunol. 2001;167:6859-6868.
39. Foss GS, Prydz H. Interferon regulatory factor 1 mediates the interferon-gamma induction of the human immunoproteasome subunit multicatalytic endopeptidase complex-like 1. J. Biol. Chem. 1999;274:35196-35202.
40. Rechsteiner M, Realini C, Ustrell V. The proteasome activator 11 S REG (PA28) and class I antigen presentation. Biochem. J. 2000;345:1-15.
41. Zammit DJ, Turner DL, Klonowski KD, Lefrancois L, Cauley LS. Residual antigen presentation after influenza virus infection affects CD8 T cell activation and migration. Immunity 2006;24:439-449.
42. Tahara EJ, Tahara H, Kanno M, Naka K, Takeda Y, Matsuzaki T, Yamazaki R, Ishihara H, Yasui W, Barrett JC, Ide T, Tahara E. G1P3, an interferon inducible gene 6-16, is expressed in gastric cancers and inhibits mitochondrial-mediated apoptosis in gastric cancer cell line TMK-1 cell. Cancer Immunol. Immunother. 2005;54:729-740.
43. Yuan W, Krug RM. Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. EMBO J. 2001;20:362-371.
44. Malakhova OA, Yan M, Malakhov MP, Yuan Y, Ritchie KJ, Kim KI, Peterson LF, Shuai K, Zhang DE. Protein ISGylation modulates the Jak-Stat signaling pathway. Genes Dev. 2003;17:455-460.